Lannett Company, Inc. (NYSE:LCI),major shareholder David Farber sold 7,500 shares of Lannett Company stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $50.00, for a total transaction of $375,000.00. Following the sale, the insider now directly owns 70,000 shares in the company, valued at approximately $3,500,000. Lannett Company, Inc. (NYSE:LCI), net profit margin is 13.30% and weekly performance is -2.69%. On last trading day company shares ended up $48.42. Analysts mean target price for the company is $47.25. Lannett Company, Inc. (NYSE:LCI), distance from 50-day simple moving average (SMA50) is 20.27%.
On June 25, 2014, Novo Nordisk A/S (ADR) (NYSE:NVO), is teaming up with NBA great and Hall of Famer Dominique Wilkins to launch Dominique’s Diabetes Dream Team, a national initiative to help adults with type 2 diabetes customize a full-court approach to managing the everyday challenges of the disease. Novo Nordisk A/S (ADR) (NYSE:NVO), in last trading session ended the day on $45.91. NVO, Gross Margin is 83.30% and its return on assets is 38.60%. Novo Nordisk A/S (ADR) (NYSE:NVO), quarterly performance is 1.57%.
Depomed Inc (NASDAQ:DEPO), issued an update on its FY14 earnings guidance on Thursday morning. The company provided EPS guidance of $0.00-$0.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26,AmericanBankingNews.com reports. The company issued revenue guidance of $200-$215 million, compared to the consensus revenue estimate of $208.61 million. Depomed Inc (NASDAQ:DEPO), shares moved down 0.45% in last trading session and was closed at $13.23, while trading in range of $13.06 – 13.28. Depomed Inc (NASDAQ:DEPO), year to date (YTD) performance is 25.05%.
On June 10, 2014, Pharmacyclics, Inc. (NASDAQ:PCYC), announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application in support of the review of its drug IMBRUVICA for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma for complete approval. The supplemental NDA is useful in the therapy of patients who have received at least one treatment previously. Pharmacyclics, Inc. (NASDAQ:PCYC), ended the last trading day at $88.48. Company weekly volatility is calculated as 3.01% and price to cash ratio as 9.62. Pharmacyclics, Inc. (NASDAQ:PCYC), showed a negative weekly performance of 0.47%.
POZEN Inc. (NASDAQ:POZN), CFO William L. Hodges unloaded 5,688 shares of the stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $9.05, for a total value of $51,476.40. Following the sale, the chief financial officer now directly owns 66,461 shares in the company, valued at approximately $601,472. POZEN Inc. (NASDAQ:POZN), net profit margin is -49.10% and weekly performance is -9.83%. On last trading day company shares ended up $8.16. Analysts mean target price for the company is $9.00. POZEN Inc. (NASDAQ:POZN), distance from 50-day simple moving average (SMA50) is -5.87%.